<DOC>
	<DOCNO>NCT00143351</DOCNO>
	<brief_summary>To assess long-term efficacy oral Ziprasidone maintenance treatment resistant schizophrenic subject benefit participation phase III ziprasidone study A1281039 ( MOZART study ) , assess efficacy ziprasidone relapse prevention schizophrenia , collect long-term data safety tolerability oral Ziprasidone</brief_summary>
	<brief_title>Mozart Relapse Study</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Subjects complete MOZART study responder Ziprasidone : Responders : patient 20 % reduction PANSS total score endpoint Mozart Study ( record V18 Mozart ) compare baseline value Patients hospitalise acute psychiatric service Written , inform consent participation . Female patient risk pregnancy must avoid remain pregnant ; already use , adequate method contraception continue Psychiatric : Subjects score great equal 5 increase least 2 point ( respect baseline value MOZART study ) one follow PANSS item : P7 ( hostility ) , G8 ( uncooperativeness ) G14 ( poor control impulse ) Subjects score equal 3 increase least 1 point ( respect baseline value MOZART study ) item 8 ( suicide ) CDSS General : Patients , MOZART study , develop one follow disease exclude : ( patient satisfy anymore one follow general exclusion criterion MOZART study ) Subjects history clinically significant and/or currently relevant haematological , renal ( include single kidney ) , hepatic , gastrointestinal , endocrine ( except current adequately treat hypo hyperthyroidism ) , pulmonary ( exclude chronic bronchitis , mild emphysema chronic obstructive pulmonary disease ) , dermatological , oncological , neurological disease , exclude tardive dyskinesia include form epilepsy ( febrile convulsion childhood acceptable ) . The subject know prior malignant disease eligible cure prior skin cancer . Controlled Type II diabetes ( glucose &lt; 180 mg/100 ml screen baseline dietary oral hypoglycemic treatment ) consider significant medical illness would exclude subject study Patients non stabilize somatic disease Acute chronic heart disease Clinically significant ECG abnormality Subjects QTc great equal 500 msec ( subject QTc great equal 450 msec &lt; 500 msec discuss cardiologist ) Concomitant treatment medication prolong QTc interval ( please review prescribe information treatment ) Subjects serum K+ outside normal range History seizure ( discuss Sponsor ) Subject confirm laboratory value deviate upper low limit normal prior study entry , except clinically insignificant deviation determine investigator Pregnant lactate woman Subjects intend donate blood blood product 4 week prior study , study 30 day study end Subjects unable unlikely follow study protocol Subjects history neuroleptic malignant syndrome develop administration antipsychotic compound Diagnosis substance dependence use DSMIV criterion ( 305.xx ) Positive urine drug screen screen amphetamine , cocaine opioids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>